PAR 12.7% 31.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2507

  1. 54 Posts.
    lightbulb Created with Sketch. 15
    The half year report states that the R&D tax incentive receivable is $7,077,840 for the period to 31/12/21.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.